FDA Declares US Neurosurgical Sponge Shortage After Medline Recall

The United States Food and Drug Administration on Wednesday May 6, 2026 added neurosurgical patties, sponges and strip devices to its national medical device shortages list, formally signaling that the country is facing a sustained gap in the supply of products used to absorb fluid and protect delicate tissue during brain and spine surgery. Listed under product code HBA, the shortage is expected by the agency to continue through the end of 2026.

The disruption stems from a recall by Medline Industries, the dominant supplier in this niche category. On March 13, 2026, Medline notified customers that higher-than-expected endotoxin levels had been identified on its branded neurosurgical pattie products, and that out-of-specification levels could be present in items already sitting on hospital shelves. The company initiated a Class 2 recall of all SKUs in its branded neuro sponge line on March 19, 2026, instructing customers to identify, quarantine and destroy the affected devices. The FDA officially posted the recall on April 30, 2026, while Health Canada had updated its own recall notice on April 9, 2026.

The recall covers a wide range of procedure kits that depend on these absorbent pads, including ENT, epistaxis, rhino, sinus, septo, nasal, stereotactic, spine, bronchoscopy and airway-related kits. Use of affected products carries the risk of febrile response, local transient inflammation, low blood pressure and nausea, which the FDA noted could require medical or surgical intervention. As of early May 2026, Medline has stated on its product page that there is no definite market re-entry date and that it continues to explore alternatives.

The shortage is significant because neurosurgical patties and sponges sit in a thin and highly specialized segment of the medical device market. Karen Niven, senior director of clinical value analysis at healthcare service provider Premier, described the recalled items as a high-risk low-frequency product, used in delicate brain and spine procedures where small errors carry outsized consequences. With Medline holding a large share of US supply under product code HBA, alternative manufacturers cannot quickly absorb the demand left by the recall, and ramp-up of production by competitors typically requires weeks of validation, sterility testing and regulatory clearance.

In its letter to healthcare providers, the FDA outlined a series of mitigation steps. Hospitals are asked to conserve neurosurgical patties, sponges and strips wherever possible, reserve them for intracranial operations and cases where no alternative is suitable, open packages only when needed to limit waste, and diversify their supply sources by qualifying additional vendors. Providers are also asked to report any supply chain challenges or suspected adverse events related to the devices, and to use clinical judgment when adapting surgical practice to lower stock levels.

For US hospitals, the practical impact is already visible in procurement teams scrambling to lock in volumes from secondary suppliers, in surgical staff being briefed on substitution protocols, and in some non-urgent neurosurgical cases being re-scheduled to preserve sponges for emergency intracranial procedures. The shortage affects thousands of neurosurgical interventions per month nationwide, ranging from tumor resections and aneurysm clippings to spine decompressions where the absorbent pads are routinely used.

Looking ahead, the FDA has said it will continue to work with other manufacturers and healthcare providers to monitor supplies, evaluate ways to mitigate patient impact and ensure that products remain available when medically necessary. Until Medline can resolve the underlying endotoxin issue at its production facilities and obtain clearance to return its branded neuro sponges to the market, US healthcare providers are expected to operate under tightened allocation and conservation rules well into the second half of 2026.